AHZ is in a rut. I have been telling this for a while. Sure they keep coming up with good announcements about vaccine development and ADAPT expansion, but the market at this stage can only look at this as more costs. These guys need to partner with a distributor for cardiocel ASAP, otherwise it won't be long before another CR. ADAPT might have more applications down the line, but can you imagine the R&D costs and further marketing costs, the mind boggles. These guys are being too ambitious for their own good. No doubt a lot of questions will be asked at the AGM of management.
AHZ is in a rut. I have been telling this for a while. Sure they...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
-0.050(0.25%) |
Mkt cap ! $387.7M | |||
| Open | High | Low | Value | Volume |
| $20.20 | $20.50 | $20.00 | $71.28K | 3.532K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 776 | $20.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.18 | 1200 | 1 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.16 |
Change
-0.050 ( 0.69 %) |
||||
| Open | High | Low | Volume | ||
| $20.17 | $20.17 | $20.09 | 129 | ||
| Last updated 15.56pm 16/05/2024 ? | |||||
| AVR (ASX) Chart |